Haemonetics Is Still Undervalued, Even After The Rally [Seeking Alpha]
Haemonetics Corporation (HAE)
Last haemonetics corporation earnings: 2/4 06:00 am
Check Earnings Report
US:NYSE Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=72118&p=irol-irhome
Company Research
Source: Seeking Alpha
HAE reported improved gross and operating margins, raised full-year EPS guidance to $4.80–$5.00, and increased free cash flow outlook to $170–210 million. The company's valuation is attractive at a 14x forward P/E, below industry averages and historical norms, with potential for multiple expansion as performance stabilizes. Despite a recent stock surge, HAE's consistent execution, product innovation, and improving fundamentals make further upside more compelling than downside risks. Arctic-Images/DigitalVision via Getty Images Thesis Haemonetics Corporation (NYSE: HAE ) is a company that makes products used to manage blood and test how well blood clots. Its main products include TEG systems (which test blood clotting), plasma collection technology, and This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of HAE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my o
Show less
Read more
Impact Snapshot
Event Time:
HAE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HAE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HAE alerts
High impacting Haemonetics Corporation news events
Weekly update
A roundup of the hottest topics
HAE
News
- Haemonetics (NYSE:HAE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $88.00 price target on the stock.MarketBeat
- Haemonetics (NYSE:HAE) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..MarketBeat
- Haemonetics (NYSE:HAE) had its price target raised by analysts at Barrington Research from $86.00 to $90.00. They now have an "outperform" rating on the stock.MarketBeat
- Haemonetics (NYSE:HAE) had its price target raised by analysts at Needham & Company LLC from $68.00 to $78.00. They now have a "buy" rating on the stock.MarketBeat
- Haemonetics (NYSE:HAE) had its price target raised by analysts at BTIG Research from $85.00 to $88.00. They now have a "buy" rating on the stock.MarketBeat
HAE
Earnings
- 11/7/25 - Beat
HAE
Sec Filings
- 11/12/25 - Form 4
- 11/6/25 - Form 10-Q
- 11/6/25 - Form 8-K
- HAE's page on the SEC website